This regulatory milestone follows news from earlier this year, when the company announced positive verification study results for its Nellcor pulse oximetry system with Nell-EQ intelligent processor. The technology was also previously granted FDA Safer Technologies Program (STeP) designation for medical devices that are reasonably expected to improve the safety of currently available devices.

“With this FDA clearance, our innovative Nell-EQ system expands the Medtronic pulse oximetry portfolio with an intelligent processing platform designed to support both clinical confidence and more inclusive care,” said Kate Benedict, president of the Medtronic Acute Care & Monitoring business, which is part of the company’s Medical Surgical Portfolio. “Our Nellcor pulse oximetry system with Nell-EQ intelligent processor builds on our longstanding commitment to delivering reliable monitoring performance for diverse patient populations across care environments.”

Pulse oximetry plays a critical role in clinical assessment and decision‑making. Yet, it is known in the industry that performance has historically varied depending on clinical conditions, patient physiology, and skin tone, which can impact signal reliability during monitoring. FDA 510(k) clearance of the Nell-EQ system comes shortly after the International Organization for Standardization (ISO) published ISO 80601-2-61:2026, at a time when evolving standards and regulatory expectations are placing greater focus on evaluating pulse oximeter performance across diverse patient populations, including defined skin tone groups.

Clinical studies for the Nell-EQ system included participants across the full range of skin tones, and the system uses advanced signal processing methods, incorporating patient-specific and sensor-specific signal characteristics to support more consistent and reliable interpretation of optical signals into SpO₂ values. In addition to SpO₂ and pulse rate, the platform supports parameters such as Perfusion Index (PI) and Heart Rate Variability (HRV).

“With our Nellcor pulse oximetry system with Nell-EQ intelligent processor, Medtronic continues to lead the industry in advancing pulse oximetry technology that helps clinicians deliver confident, equitable care for every patient, in every care setting,” said Dr. Jeb Denny, chief medical officer of the Medtronic Acute Care & Monitoring business. “Our continued leadership reflects a deep commitment to inclusive innovation and equipping clinicians with trusted technology that supports high-quality care for all patients across the continuum of care.”

Nellcor pulse oximetry technology with Nell-EQ intelligent processor will be available for sale globally in the upcoming months. Medtronic plans to support the rollout with clinician education and training resources.

Evidence shows the company’s Nellcor pulse oximeters lead the way in equitable patient monitoring,^‡1,2 and Medtronic continues to partner and invest in professional education and continued innovation. Educational resources on how pulse oximeters work and tips for getting the most accurate SpO₂ readings from current devices are available through the Medtronic Academy. Medtronic remains committed to delivering better outcomes for all patients through continued innovation and is proud to participate in the STeP program. Learn more about equitable monitoring and the company’s commitment to patient safety at health equity in pulse oximetry monitoring.

Acute Care and Monitoring products should not be used as the sole basis for diagnosis or therapy and are intended only as an adjunct in patient assessment.

Note: Oxygen saturation accuracy can be affected by certain environmental, equipment, and patient physiologic conditions that influence readings of SpO₂.

References

‡ Based on two studies (not funded by Medtronic) not designed for head-to-head comparison of devices. One study enrolled 146 healthy subjects in the 92-96% saturation range and examined paired readings from Nellcor N-595 and Masimo Radical 7* pulse oximeters generated simultaneously. The second study enrolled 319 children with different skin tones undergoing cardiac catheterization and examined paired readings from Nellcor disposable SpO2 adhesive sensors and Masimo reusable child/adult clip sensors generated simultaneously.

1. Gudelunas MK, Lipnick M, Hendrickson C, et al. Low Perfusion and Missed Diagnosis of Hypoxemia by Pulse Oximetry in Darkly Pigmented Skin: A Prospective Study. Anesth Analg. 2024;138(3):552-561. doi:10.1213/ANE.0000000000006755
2. Starnes JR, Welch W, Henderson CC, Hudson S, Risney S, Nicholson GT, Doyle TP, Janssen DR, Londergan BP, Parra DA, Slaughter JC, Aliyu MH, Graves JA, Soslow JH. Pulse Oximetry and Skin Tone in Children. N. Engl J Med. 2025 Feb 12. doi: 10.1056/NEJMc2414937. Epub ahead of print.

About Medtronic
Bold thinking. Bolder actions. We are Medtronic. Medtronic plc, headquartered in Galway, Ireland, is the leading global healthcare technology company that boldly attacks the most challenging health problems facing humanity by searching out and finding solutions. Our Mission — to alleviate pain, restore health, and extend life — unites a global team of 95,000+ passionate people across more than 150 countries. Our technologies and therapies treat 70 health conditions and include cardiac devices, surgical robotics, insulin pumps, surgical tools, patient monitoring systems, and more. Powered by our diverse knowledge, insatiable curiosity, and desire to help all those who need it, we deliver innovative technologies that transform the lives of two people every second, every hour, every day. Expect more from us as we empower insight-driven care, experiences that put people first, and better outcomes for our world. In everything we do, we are engineering the extraordinary. For more information on Medtronic, visit medtronic.com and follow Medtronic on LinkedIn.

Any forward-looking statements are subject to risks and uncertainties such as those described in Medtronic’s periodic reports on file with the Securities and Exchange Commission. Actual results may differ materially from anticipated results.

Contacts
Amanda Bartschenfeld
Communications
amanda.k.bartschenfeld@medtronic.com

Ingrid Goldberg
Investor Relations
investorrelations@medtronic.com

LAUSANNE, Switzerland, June 8, 2026 /3BL/ – Tetra Pak has today launched its full-year 2025 (FY25) Sustainability Report, outlining how its continued emissions reductions are supporting greater resilience across the global food system.

In 2025, the company achieved a 34% reduction in greenhouse gas (GHG) emissions across its value chain since 2019,¹ representing an improvement of almost 12 percentage points compared with the previous year,² while also reducing emissions across its own operations by 56%³ and reaching 97% renewable energy consumption.

This progress reflects Tetra Pak’s growing focus on translating emissions reductions into long-term food system resilience. By directing efforts and investment towards areas where it can deliver the greatest long-term value, the company aims to support more efficient, robust food production while continuing to reduce its environmental impact.

Adolfo Orive, President & CEO at Tetra Pak, comments: “Feeding a growing global population is becoming ever more complex as environmental risks intensify. This is why we remain firmly committed to strengthening the resilience of the world’s food systems. With clear, measurable targets in place, 2025 marked a year of tangible progress, including passing the milestone of a one‑third reduction in greenhouse gas emissions across our value chain. Achieving lasting change depends on collaboration, and we look forward to continuing to work closely with our customers and partners to turn shared ambition into enduring progress.”

To guide its actions and investment decisions, and to support more efficient, resilient food systems, Tetra Pak developed and launched an integrated climate and nature risk and opportunity assessment in 2025. The assessment identified priority risks and opportunities to build resilience across the company’s operations and value chain, supported by plans to address each priority area. Tetra Pak also revised its Approach to Nature framework, reflecting learnings to ensure it remains relevant in a rapidly evolving industry landscape. As part of this, the company introduced new or updated targets in response to developments in specific action areas.

Several initiatives and innovations were introduced or developed in 2025 to help customers significantly reduce utility, material and energy use by embedding a total cost of ownership (TCO) mindset that assesses the overall lifecycle cost of equipment. This was reinforced by the launch of Tetra Pak^® Factory OS, a next-generation automation and digital ecosystem that combines modular, scalable and smart technologies with deep industry and equipment expertise to help customers better understand and mitigate losses in their operations.

This commitment to sustainable food production was further strengthened with the expansion of Tetra Pak’s global network of innovation centres. 2025 saw the launch of a new Product Development Centre in Cholet, France, a new Customer Innovation Centre in Bangkok, Thailand, and a Tetra Pak^® New Food Technology Development centre in Karlshamn, Sweden. These centres give customers the space, support and expertise to test innovations and scale products to deliver food safely around the world.

Overall, 2025’s progress sees Tetra Pak on track to meet its long-term climate targets. These include achieving a 46% reduction in value chain GHG emissions by 2030, increasing renewable electricity consumption across operations to 100% by 2030, and reaching net-zero emissions by 2050.

Other notable achievements shared in the FY25 Sustainability Report include:

• Investing approximately €100 million in packaging research and development to address the sustainability of Tetra Pak packages. This investment led to a world-first paper barrier for juice packages, delivering a 43% lower carbon footprint than an aseptic package with an aluminium foil layer and a fossil-based polymer.
• Renewing its focus on decarbonising food systems by signing a Memorandum of Understanding (MoU) with the United Nations Industrial Development Organization (UNIDO) at COP30, to scale innovation in this area.
• Providing 68 million children across 52 countries with milk or other beverages in its packages through school feeding programmes, an increase of two million children and three additional countries from 2024.
• Conducting an in-depth review of priority human rights impacts along the full value chain.
• Expanding restoration efforts through the Araucaria Conservation Project, with over 1,600 hectares added in 2025 alone, more than doubling the total area of land under restoration in a single year.

The FY25 Sustainability Report is available online now.

Download pdf

Media contacts
PR agency contact:
Olivia Tomblin
Brands2Life for Tetra Pak
Tel: +44 207 592 1200
tetrapakcorporate@brands2life.com

¹ Scope 1, 2 and 3 GHG emissions, compared to a 2019 baseline.

² Full year 2024.

³ Scope 1, 2 and business travel GHG emissions, compared to a 2019 baseline.

At a hospital, there’s no room for downtime. 

Every system, including heating, cooling and lighting, has to work seamlessly to support patient care around the clock. For Holy Name Medical Center, an accredited, not-for-profit hospital in Teaneck, New Jersey, that reliability is essential. 

Serving more than 350,000 outpatients and 27,000 admissions each year, Holy Name supports patients at every stage, from prevention and early intervention to treatment and rehabilitation. That role makes it important for the hospital’s building systems to operate without disruption so care can continue uninterrupted. 

Improving systems without interrupting care 

Hospitals cannot pause operations for construction. Through our Engineered Solutions Program, one of several energy efficiency offerings we provide to businesses, our project team worked closely with hospital staff to phase the work and put temporary systems in place where needed. 

We worked alongside engineering consultants and union construction labor to complete a comprehensive set of upgrades across the facility.

Lighting, heating and cooling systems, as well as controls and critical equipment, were modernized to improve performance, reliability and comfort.  

How do hospital energy upgrades help improve reliability and lower operating costs? 

The completed upgrades are helping Holy Name reduce energy use, improve system reliability and better manage operating costs, all without disrupting patient care.  

The project represents a $12.7 million investment, supported by PSE&G incentives that covered approximately 35% of the total cost. The remaining balance is being repaid over time through interest-free, on-bill repayment, helping make the upgrades more manageable for the hospital. 

As the improvements take effect, Holy Name is expected to reduce energy use by more than 5.2 million kilowatt-hours of electricity and 38,000 therms of natural gas each year. That’s roughly equivalent to the annual energy use of more than 590 homes. 

The entire project took about four years, with construction beginning in December 2021 and wrapping up in December 2025. In the first year following completion, the hospital is expected to see about $750,000 in energy cost savings. Savings will change over time as equipment ages and on-bill repayment is completed, but the project helps reduce energy use, improve system performance and make energy costs more manageable.

For a not-for-profit hospital, those savings can make a meaningful difference. They help create flexibility to invest in patient care, upgrade equipment and continue supporting the programs and services the community relies on. 

“Cost-effective energy efficiency is about responsible stewardship, ensuring our health system operates sustainably while directing more resources to patient care and safety,” said Steven Mosser, executive vice president of Operations at Holy Name. 

Beyond energy savings: Improving day-to-day operations 

Beyond the energy savings, the upgrades have also helped improve day-to-day operations across the hospital. Systems are easier to monitor, maintenance needs have been reduced and teams have better visibility into how the building is performing. 

While many of the upgrades happened behind the scenes, they’ve helped support a more comfortable and consistent environment for patients and staff, highlighting how energy efficiency can help essential institutions operate more effectively so they can continue doing what matters most: caring for people. 

This project shows how energy efficiency programs, along with incentives and on-bill repayment, can help hospitals move forward with major improvements while keeping their operations running and focused on patient care.”

-Rachael Fredericks, Director of Energy Services at PSE&G 

To learn more about how your organization can benefit from our suite of energy efficiency programs, visit mybizenergy.pseg.com. 

Click here to listen to the podcast.

The initiative reinforces the strategic partnership between CNH and TIM in the development of connectivity solutions for agriculture, building on already well established experiences such as the Connected Farm Case IH project in Água Boa (MT). Over three harvest seasons, the project delivered significant gains in productivity, operational efficiency, cost reduction, and lower environmental impact through the use of connected technologies. In this context, connectivity acts as a key infrastructure catalyst for rural communities, bringing high quality internet access to local schools and healthcare facilities.

In the case of connected machines in the field, beyond cost reduction and productivity gains, they also generate data that goes far beyond indicating whether the machine is operating properly. Through the Case IH and New Holland monitoring centers, a specialized team provides support to dealerships and develops projects focused on increasing machine uptime in the field.

Expected to be implemented within 18 months, the 97 towers should connect about 1.5 million hectares in Minas Gerais, benefiting more than 200 thousand people living in rural areas without connectivity, including about 47 rural schools, 11 basic health units and approximately 11 thousand properties.

Read the full story here.

“The U.S. Soccer Foundation was founded more than three decades ago on a simple but powerful belief: that soccer can change lives,” said Ed Foster-Simeon, President & CEO of the U.S. Soccer Foundation. “That belief continues to guide our work, and this year’s honorees exemplify it through their commitment to expanding access and uplifting young people in under-resourced communities. We’re proud to recognize their leadership and the lasting impact they’re making.”

The LA Galaxy was awarded the Kevin Payne Community Impact Award, presented to a professional team with a track record that exemplifies what it means to leverage soccer to engage youth and strengthen under-resourced communities.

Since 2015, the LA Galaxy have partnered with the U.S. Soccer Foundation to create more safe places to play across the greater LA region, installing eight mini-pitches, including one recently in Pasadena after the devastation caused by the recent wildfires.

“We’re honored to be recognized by the U.S. Soccer Foundation with the Kevin Payne Community Impact Award,” said Tom Braun, President and Chief Operating Officer, LA Galaxy. “At the Galaxy, we believe in the power of soccer to bring communities together and create real opportunity for young people. Through our continued partnership with the U.S. Soccer Foundation, we’re proud to help expand access to safe places to play and support youth across Los Angeles as they build confidence, develop life skills, and pursue their full potential.”

The 2026 awardees were honored during the 12th Congressional Soccer Match at Audi Field. For more information on the honorees, read the U.S. Soccer Foundation release here.

For more than 30 years, the U.S. Soccer Foundation has been the leading force focused on advancing soccer as a vehicle for social impact. In three decades, the Foundation has worked collaboratively with 1,000 national and local partners to positively impact youth in under-resourced communities – delivering proven programs that foster improved health and well-being at a time when kids need it most. Last year, the U.S. Soccer Foundation engaged 1.2 million youth in its programs proven to improve the health and well-being of participants. The Foundation has installed more than 900 mini-pitches nationwide, on track to create 1,000 by the end of 2026.

ABOUT THE U.S. SOCCER FOUNDATION 
As the national leader for sports-based youth development in under-resourced areas, the U.S. Soccer Foundation is on a mission to let soccer do what it does: change absolutely everything. Founded as a legacy of the 1994 FIFA World Cup, the Foundation provides underserved communities access to innovative play spaces and evidence-based soccer programs that instill hope, foster well-being, and help youth achieve their fullest potential. Headquartered in Washington, D.C., the U.S. Soccer Foundation is a 501(c)(3) organization. For more information visit www.ussoccerfoundation.org or follow us on LinkedIn and Instagram.

ABOUT THE LA GALAXY

The LA Galaxy are Major League Soccer’s most successful club. Based in Carson, Calif. at Dignity Health Sports Park, the Galaxy have won the MLS Cup a record six times (2002, 2005, 2011, 2012, 2014, 2024), the MLS Supporters’ Shield four times (1998, 2002, 2010, 2011) and the Lamar Hunt U.S. Open Cup twice (2001, 2005), and one Concacaf Champions Cup (2000) since their inception in 1996. Under the direction of LA Galaxy President of Business Operations and Chief Operating Officer Tom Braun and LA Galaxy General Manager Will Kuntz, the Galaxy are the premier club in MLS, with stars like Landon Donovan, David Beckham, Robbie Keane, Steven Gerrard, Zlatan Ibrahimović, Javier Hernandez, Cobi Jones, Riqui Puig, and Marco Reus representing LA over the team’s 30 seasons in MLS. For more information on the LA Galaxy, visit www.lagalaxy.com.

“Americans spend 90% of their lives indoors, breathing air that can be two to five times more polluted than what’s outside, yet federal investment in indoor air quality has never matched the scale of the problem,” said Kenneth Mendez, President and CEO of AAFA. “ARPA-H is changing that. BREATHE and PRO-MICROBE represent the kind of bold, patient-centered innovation that millions of Americans living with asthma and allergies have been waiting for, and AAFA is proud to recognize ARPA-H for this important work.”

The award honors ARPA-H for its groundbreaking work through its BREATHE and PRO-MICROBE programs — two bold R&D initiatives helping to revolutionize how indoor environments are understood, monitored and optimized to protect and enhance human health. Together, the programs are advancing next-generation technologies designed to continuously measure indoor air quality, estimate health risks in real time and support interventions that promote cleaner, healthier indoor environments.

“Optimizing our buildings for health is one of the single greatest public health opportunities of our time,” said Rachel Hodgdon, President and CEO of IWBI. “We are excited to recognize ARPA-H for serving as a massive accelerant to meet this moment. Their groundbreaking work is driving the market to transform indoor air quality to not only prevent airborne illness, but actively extend human health span, boost cognitive performance and deliver well-being at scale.”

By accelerating innovations that can help prevent illness, improve well-being and enhance longevity, the ARPA-H programs hold enormous promise for children with asthma and allergies, adults with COPD, hospitalized patients and other vulnerable populations. The initiatives are also helping position the United States as a global leader in the rapidly expanding healthy buildings sector — driving innovation that supports human performance, productivity, resilience and long-term economic competitiveness.

“It is well understood across the building sector that operations and maintenance have a significant impact on the health, safety and productivity of building occupants throughout the built environment,” said Michael V. Geary, CAE, President and CEO of IFMA. “We congratulate ARPA-H and thank them for their leadership in advancing tools and research that are invaluable to facility managers around the globe.”

The award was presented to ARPA-H leadership today during ARPA-H’s Healthy Buildings Demo Day in Washington, D.C., where project awardees showcased hands-on demonstrations highlighting cutting-edge innovations aimed at transforming indoor air quality, advancing healthier buildings and strengthening public health.

“We estimate poor indoor air quality drives over $180 billion in healthcare costs each year in this country. That’s unacceptable,” said ARPA-H Director Alicia Jackson, Ph.D. “That massive impact on the American people demands an innovative, flexible solution we can roll out in years—not decades. With BREATHE and PRO-MICROBE, ARPA-H is redefining what’s possible in the built environment to protect every American from respiratory illnesses and the respiratory effects of chronic conditions.”

“Parents shouldn’t have to send their kids to school worrying the environment could exacerbate asthma, and patients shouldn’t have to enter a hospital just to leave with a new airborne illness,” said ARPA-H BREATHE and PRO-MICROBE Program Manager Jessica Green, Ph.D. “I’m incredibly proud of the rapid progress our awardees have made. We are headed toward a new era in indoor air quality that will translate to healthier kids, safer patients, dramatic cost savings, and far greater peace of mind.”

About the Asthma and Allergy Foundation of America
Founded in 1953, AAFA is the oldest and largest non-profit patient organization dedicated to saving lives and improving the quality of life for people affected by asthma and allergic diseases through support, advocacy, education, and research. AAFA offers extensive support for individuals and families affected by asthma and allergic diseases, such as food allergies and atopic dermatitis (eczema). Through its online patient support communities, network of regional chapters, and collaborations with community-based groups, AAFA empowers patients and their families by providing practical, evidence-based information and community programs and services. AAFA is the first asthma and allergy patient advocacy group that is certified to meet the standards of excellence set by the National Health Council. For more information, visit: aafa.org and kidswithfoodallergies.org.

About the International Facility Management Association
Founded in 1980, the International Facility Management Association (IFMA) is the world’s largest, most widely recognized association for facility management (FM) professionals. Supporting more than 25,000 members in 140 countries, IFMA’s Vision is to lead the future of the built environment to make the world a better place. IFMA is a key contributor to the development of international FM standards and works with decision makers to inform FM-related policy. IFMA provides career resources and continuing education, offers three industry-respected credentials, maintains the largest repository of FM-related content on the web and hosts year-round global events. Learn more at ifma.org.

About the International WELL Building Institute
The International WELL Building Institute (IWBI) is a public benefit corporation and the global authority for transforming health and well-being in buildings, organizations and communities. In pursuit of its public-health mission, IWBI mobilizes its community through the development and administration of the WELL Building Standard (WELL), WELL for residential, WELL Community Standard, its WELL ratings and management of the WELL AP credential. IWBI also translates research into practice, develops educational resources and advocates for policies that promote people-first places for everyone, everywhere. More information on WELL can be found here.

International WELL Building Institute, IWBI, the WELL Building Standard, WELL v2, WELL Certified, WELL AP, WELL EP, WELL Score, The WELL Conference, We Are WELL, the WELL Community Standard, WELL Health-Safety Rated, WELL Performance Rated, WELL Equity Rated, WELL Equity, WELL Coworking Rated, WELL Residence, Works with WELL, WELL and others, and their related logos are trademarks or certification marks of International WELL Building Institute pbc in the United States and other countries.

Media contact:
media@wellcertified.com

View original content here.

The event brought industry talent and executives from AEG and across the entertainment sector together and offered students a chance to participate in panel discussions, mentoring sessions and learn first-hand about jobs in the sports and live event industry.

The day kicked off with lunch at L.A. LIVE where students were able to meet AEG employees representing the Talent Acquisition team, Black Equity Employee Network Group and Goldenvoice Black. Afterwards the students received a behind-the-scenes tour of Crypto.com Arena and concluded with a networking session with various AEG business units and EICOP partners at Peacock Theater.

The Entertainment Industry College Outreach Program is a non-profit educational arts workforce development organization, dedicated to educating, training, and recruiting the best and brightest student leaders from our nation’s Historically Black Colleges, Universities and other Minority Serving Institutions for careers across all aspects of the entertainment, music, sports, gaming and tech industries. Click here to learn more about the organization.

GALWAY, Ireland, June 4, 2026 /3BL/ – Medtronic, a global leader in healthcare technology, today announced its first cohort of Medtronic Spark Scholarship recipients, recognizing 100 exceptional students from low-income households pursuing careers in health tech. This marks a significant milestone in Medtronic Spark’s global 10-year initiative to propel 1 million students into health tech careers.

The inaugural scholarship cohort represents 12 home countries and was selected from a pool of more than 1,500 applicants across 42 countries. Each recipient receives:

• Financial support for educational expenses, renewable for up to four years
• Career building experiences, which may include Medtronic mentorship, coaching, networking support, and more
• Availability of an emergency support fund to close the gap when facing unexpected episodic hardships that can derail academic progress

“The Medtronic Spark Scholarship gives students from around the world an opportunity to pursue their passion for improving people’s lives,” said Dr. Sally Saba, President of Medtronic Foundation. “I’m inspired and humbled by their stories of grit, perseverance, and determination to seek an education that allows them to serve and heal others. By combining financial support with mentorship, career guidance, and additional services, we’re creating a holistic support system that removes barriers and empowers students to graduate and thrive in health tech careers.”

“I’m inspired by the challenge of turning breakthrough science into technologies people can trust, access, and benefit from,” said Nathan, a Medtronic Spark scholarship recipient studying biomedical engineering and finance at Washington University in St. Louis. “I hope to build and scale health innovations—especially in areas like neurotechnology.”

Medtronic will award up to 100 new scholarships each year over the next 10 years to students residing in 70+ eligible countries. Applications will re-open in October 2026.

“I have always dreamed of helping people in difficult situations achieve a better quality of life through science,” said Valeria, a Medtronic Spark scholarship recipient at the Instituto Teccnológico y de Estudios Superiores de Monterrey in Mexico. “Receiving the Medtronic Spark scholarship motivates me to continue pursuing this dream, to move forward with determination along the career path I am passionate about.”

Visit https://www.medtronicspark.com/scholarship/ to learn more and sign up to receive updates.

About Medtronic
Bold thinking. Bolder actions. We are Medtronic. Medtronic plc, headquartered in Galway, Ireland, is the leading global healthcare technology company that boldly attacks the most challenging health problems facing humanity by searching out and finding solutions. Our Mission — to alleviate pain, restore health, and extend life — unites a global team of 95,000+ passionate people across more than 150 countries. Our technologies and therapies treat 70 health conditions and include cardiac devices, surgical robotics, surgical tools, patient monitoring systems, and more. Powered by our diverse knowledge, insatiable curiosity, and desire to help all those who need it, we deliver innovative technologies that transform the lives of two people every second, every hour, every day. Expect more from us as we empower insight-driven care, experiences that put people first, and better outcomes for our world. In everything we do, we are engineering the extraordinary. For more information on Medtronic, visit www.Medtronic.com and follow Medtronic on LinkedIn.

Any forward-looking statements are subject to risks and uncertainties such as those described in Medtronic’s periodic reports on file with the Securities and Exchange Commission. Actual results may differ materially from anticipated results.

Contacts:
Justin Paquette
Public Relations
+1-612-271-7935

Ingrid Goldberg
Investor Relations
+1-763-505-2696

• New World screwworm has officially reached the United States, with the first confirmed case in U.S. livestock in Texasi
• New World screwworm can infest any warm-blooded animals – including livestock and pets – posing a significant threat to animal health, welfare, and producer livelihood
• Elanco offers a portfolio of options for both livestock and pets that can treat infestations caused by New World screwworm larvae

INDIANAPOLIS, June 4, 2026 /3BL/ – Elanco Animal Health Incorporated (NYSE: ELAN) today reaffirms its commitment to providing veterinarians, livestock producers, and pet owners with resources and treatment options for their animals against the escalating threat posed by New World screwworm (NWS). The fly recently reached the United States, with the first case confirmed in U.S. livestock in Texas.i

The emergence of New World screwworm in the U.S. creates a threat for veterinarians, livestock producers and pet owners that has not been seen north of the Florida Keys since the fly was eradicated from the United States more than 50 years ago.ii New World screwworm (Cochliomyia hominivorax) larvae feed on living tissue and can affect a wide range of warm-blooded animals, including livestock, companion animals, wildlife, and even humans.ii

“New World screwworm could have a devastating impact on animal health, welfare, and producer livelihoods,” said Jeff Simmons, President and CEO, Elanco Animal Health. “We want to thank the FDA, EPA and USDA, for all their work to prepare for this threat. We’re committed to supporting our customers during this challenging time by delivering innovation, scientific expertise, and available resources to help treat New World screwworm and support the health and well-being of animals.”

With more than 70 years of animal health experience, including helping mitigate, prevent and treat New World screwworm in other parts of the world, With more than 70 years of animal health experience, including helping mitigate, prevent and treat New World screwworm in other parts of the world, Elanco is working alongside the U.S. animal health industry to help them fight against this parasite, offering a portfolio of options for pets and livestock that can help treat New World screwworm larvae infestations.

Available Elanco Treatment and/or Prevention Options 

Negasunt Powder and Tanidil will be available only through the U.S. Animal Plant Health and Inspection Service (APHIS) and its National Veterinary Stockpile. They will be distributed in coordination with state animal health officials and federally recognized tribal agencies. In the near future, APHIS will share additional information about the requirements for use, including tracking and reporting requirements and required safety and personal protective equipment.

As New World screwworm enters the United States, Elanco is committed to working alongside producers as they continuously evolve management practices and to help them implement prevention and treatment protocols to use the right product at the right time.

To learn more about Elanco’s ongoing efforts and historical perspective on New World screwworm, please visit our previous coverage:

• Elanco’s Negasunt Powder (Coumaphos, Propoxur, Sulfanilamide Topical Powder) and Tanidil (Coumaphos, Propoxur) Receive Emergency Authorization for Use Against New World Screwworm in Livestock 
• Elanco’s Credelio Quattro-CA1 (lotilaner, moxidectin, praziquantel, and pyrantel chewable tablets) Receives First FDA Conditional Approval for Treatment of New World Screwworm in Dogs 
• Elanco’s Credelio CAT (lotilaner) Receives First FDA Emergency Use Authorization (EUA) for Treatment of New World Screwworm (NWS) in Cats 
• Elanco’s Credelio (lotilaner) Receives First Ever FDA Emergency Use Authorization (EUA) against New World Screwworm (NWS) in Dogs 

To learn more about New World screwworm (NWS) using the following resources:

• USDA NWS Alert and Fact Sheet 
• NCBA NWS Resources 
• FDA Information for Veterinarians on NWS 

i USDA Confirms Presence of New World Screwworm in the United States | Animal and Plant Health Inspection Service 
ii “New World Screwworm.” www.aphis.usda.gov, www.aphis.usda.gov/livestock-poultry-disease/cattle/ticks/screwworm.

PM-US-26-1137

About Elanco Animal Health 
Elanco Animal Health Incorporated is a global leader in animal health dedicated to innovating and delivering products and services to prevent and treat disease in farm animals and pets, creating value for farmers, pet owners, veterinarians, stakeholders and society as a whole. With more than 70 years of animal health heritage, we are committed to breaking boundaries and going beyond to help our customers improve the health of animals in their care, while also making a meaningful impact on our local and global communities. At Elanco, we are driven by our vision of Food and Companionship Enriching Life and our purpose – all to Go Beyond for Animals, Customers, Society and Our People. Learn more at www.elanco.com.

Indications for Credelio Quattro/Credelio Quattro-CA1 
Credelio Quattro is indicated for the prevention of heartworm disease and the treatment and control of roundworm, hookworm, and tapeworm infections. Credelio Quattro kills adult fleas and is indicated for the treatment and prevention of flea infestations and the treatment and control of tick infestations for 1 month in dogs and puppies 8 weeks of age and older and weighing 3.3 pounds or greater. Credelio Quattro is indicated for the prevention of Lyme disease infections as a direct result of killing black-legged ticks.

Credelio Quattro-CA1 is conditionally approved for the treatment of infestations caused by New World screwworm (NWS) larvae in dogs and puppies 8 weeks of age and older and weighing 3.3 pounds or greater.

Important Safety Information for Credelio Quattro/Credelio Quattro-CA1 
Lotilaner, an ingredient in Credelio Quattro/Credelio Quattro-CA1, belongs to the isoxazoline class and has been associated with neurologic adverse reactions like tremors, incoordination, and seizures even in dogs without a history of seizures. Use with caution in dogs with a history of seizures or neurologic disorders. Dogs should be tested for existing heartworm infections before Credelio Quattro/Credelio Quattro-CA1 administration as it is not effective against adult heartworms. The safe use in breeding, pregnant, or lactating dogs has not been evaluated. The most frequently reported adverse reactions in clinical trials were vomiting and diarrhea.

Credelio Quattro-CA1 is conditionally approved by the FDA pending a full demonstration of effectiveness under application number 141-619. If you suspect that your dog is infested with NWS larvae, seek veterinary care immediately for treatment to include removal of larvae and appropriate wound care.

For complete safety information, please see the Credelio Quattro/Credelio Quattro-CA1 product label or ask your veterinarian.

Emergency Use Authorization of Credelio (lotilaner) Chewable Tablets for New World Screwworm (NWS) 

The U.S. Food and Drug Administration (FDA) has issued an Emergency Use Authorization (EUA) for the emergency use of the approved product Credelio (lotilaner) chewable tablets for the treatment of infestations caused by NWS (Cochliomyia hominivorax) larvae (myiasis) in dogs and puppies. Credelio is not approved for this use.

Credelio (lotilaner) is approved for other uses in dogs and puppies.

For additional information on the EUA, please refer to the Credelio NWS Fact Sheet.

Limitations of Authorized Use 
Credelio (lotilaner) chewable tablets is authorized for this use only for the duration of the declaration that circumstances exist justifying the authorization of the emergency use of Credelio (lotilaner) chewable tablets under section 564(b)(1) of the Federal Food, Drug, and Cosmetic Act (FD&C Act), 21 U.S.C. § 360bbb-3(b)(1), unless the authorization is terminated or revoked sooner.

Indications for Credelio 
Credelio kills adult fleas and is indicated for the treatment and prevention of flea infestations and treatment and control of tick infestations (lone star tick, American dog tick, black-legged tick, brown dog tick, and longhorned tick) for one month in dogs and puppies 8 weeks and older and 4.4 pounds or greater. Credelio is indicated for the prevention of Lyme disease infections as a direct result of killing black-legged ticks.

Important Safety Information for Credelio 
Lotilaner is a member of the isoxazoline class of drugs. This class has been associated with neurologic adverse reactions including tremors, incoordination, and seizures. Seizures have been reported in dogs receiving this class of drugs, even in dogs without a history of seizures. Use with caution in dogs with a history of seizures or neurologic disorders. The safe use of Credelio in breeding, pregnant or lactating dogs has not been evaluated. The most frequently reported adverse reactions are weight loss, elevated blood urea nitrogen, increased urination, and diarrhea. For complete safety information, please see Credelio product label or ask your veterinarian.

Emergency Use Authorization for Credelio CAT (lotilaner) for New World Screwworm (NWS) 
The U.S. Food and Drug Administration (FDA) has issued an Emergency Use Authorization (EUA) for the emergency use of the approved product Credelio CAT (lotilaner) for the treatment of infestations caused by NWS (Cochliomyia hominivorax) larvae (myiasis) in cats and kittens. Credelio CAT is not approved for this use.

Credelio CAT is approved for other uses.

For additional information on the EUA, please refer to the Credelio Cat NWS Fact Sheet.

Limitations of Authorized Use 
Credelio CAT (lotilaner) is authorized for this use only for the duration of the declaration that circumstances exist justifying the authorization of the emergency use of Credelio CAT (lotilaner) under section 564(b)(1) of the Federal Food, Drug, and Cosmetic Act (FD&C Act), 21 U.S.C. § 360bbb-3(b)(1), unless the authorization is terminated or revoked sooner.

Indications for Credelio CAT 
Credelio CAT kills adult fleas and is indicated for the treatment and prevention of flea infestations for one month in cats and kittens 8 weeks of age and older and weighing 2 pounds or greater.

Credelio CAT is also indicated for treatment and control of black-legged tick infestations for one month in cats and kittens 6 months of age and older and weighing 2 pounds or greater.

Important Safety Information for Credelio CAT 
Lotilaner is a member of the isoxazoline class of drugs. This class has been associated with neurologic adverse reactions including tremors, incoordination and seizures. Neurologic adverse reactions have been reported in cats receiving isoxazoline class drugs, even in cats without a history of neurologic disorders. Use with caution in cats with a history of neurologic disorders. The safety of Credelio CAT has not been established in breeding, pregnant and lactating cats. The effectiveness of Credelio CAT against black-legged ticks in kittens less than 6 months of age has not been evaluated. The most frequently reported adverse reactions are weight loss, rapid breathing and vomiting. For complete safety information, please see Credelio CAT product label or ask your veterinarian.

Emergency Use Authorization of Negasunt Powder (coumaphos, propoxur, and sulfanilamide topical powder) for New World Screwworm (NWS)

WARNING: Neurotoxicity. Read full Fact Sheet for complete information.

• Coumaphos and propoxur can cause neurotoxicity. May be fatal if swallowed. May be fatal if inhaled. Harmful if absorbed through skin. Causes moderate eye irritation. Do not breathe dust. Avoid contact with eyes, skin, or clothing.
• Use only with appropriate personal protective equipment (PPE): coveralls worn over long-sleeve shirt and long pants, shoes, socks, and protective eyewear; chemical-resistant gloves made of barrier laminate, butyl rubber (≥ 14 mils), nitrile rubber (≥14 mils), neoprene rubber (>14 mils), natural rubber (≥14 mils), polyethylene, polyvinyl chloride (PVC) ≥14 mils, or Viton (>14 mils); and a minimum of a NIOSH-approved elastomeric half mask respirator consisting of protection factor (PF) 10 fitted with organic vapor (OV) cartridges and combination R or P filters; or a NIOSH-approved gas mask with OV canisters; or a NIOSH-approved powered air purifying respirator with OV cartridges and combination HE filters.
• This product is toxic to mammals, birds, fish, and aquatic invertebrates.

The U.S. Food and Drug Administration (FDA) has issued an Emergency Use Authorization (EUA) for the emergency use of the unapproved product Negasunt Powder for the prevention and treatment of infestations caused by New World screwworm (Cochliomyia homnivorax) larvae (myiasis) in cattle, swine, goats, sheep, horses, donkeys, domestic hybrid equids, and captive wild, exotic, and zoo mammals. Negasunt Powder is not approved for this use.

For use by employees of federal, state, local, and federally recognized tribal agencies, and persons working under their authority and at their direction. Also for use by or on the order of a licensed veterinarian in NWS infested zones and adjacent surveillance zones as defined by the U.S. Department of Agriculture (USDA).

For additional information on the EUA and for complete safety information, please refer to the Negasunt Powder NWS Fact Sheet.

Limitations of Authorized Use 
It is a violation of federal law to use this drug product other than as directed in the authorized Fact Sheet.

Treated animals must not be slaughtered for human consumption within 28 days of the last treatment.

A milk discard time has not been established for this product; do not use in animals producing milk for human consumption.

A withdrawal period has not been established for this product in pre-ruminating calves; treated calves and calves born to treated cows must not be processed for veal.

Do not use in horses intended for human consumption. Do not use in domestic indoor pets (e.g., dogs, cats, rodents, rabbits) nor in residences. Do not use in birds. Do not use in free-ranging wildlife.

To avoid overexposure, each individual person cannot treat more than 3 large wounds (>2 inches diameter) a day or more than 30 small superficial wounds (≤2 inches diameter) a day (or an equivalent thereof) with Negasunt Powder or any other coumaphos-containing products.

Negasunt Powder is authorized for this use only for the duration of the declaration that circumstances exist justifying the authorization of the emergency use of Negasunt Powder under section 564(b)(1) of the Federal Food, Drug, and Cosmetic Act (FD&C Act), 21 U.S.C. § 360bbb-3(b)(1), unless the declaration is terminated or the authorization is revoked sooner.

Federal law prohibits the extra-label use of this drug.

Additional Important Safety Information 
Not for use in humans. Keep out of reach of children. Only handlers wearing required PPE may be in the area during application. Do not apply in a confined, non-ventilated area; provide thorough ventilation. Call a poison control center or doctor immediately for treatment advice if Negusant Powder is swallowed, inhaled, on skin or clothing, or in eyes. Sulfonamides are contraindicated in animals that are hypersensitive to them and in animals with severe renal or hepatic impairment. For external use only on animals. Do not contaminate water, feed, troughs, feed handling equipment, or milk or meat handling equipment. Use with caution in very young, weak, or debilitated animals. In the case of overdose, treat with atropine sulfate or pralidoxine chloride (2-PAM) as soon as possible. The most common adverse reactions associated with organophosphate and carbamate toxicity in animals include frequent urination and defecation, muscle twitching, and watering eyes.

Important Information about Tanidil 
Tanidil is an unregistered product for distribution and use only under a Section 18 emergency exemption. The Section 18 labeling must be in the possession of the user at the time of pesticide application. This product may only be used to prevent or control New World screwworm in and on animal wounds on labeled animal host species.

For use only by federal, state, local, and federally recognized tribal agencies, and persons working under their supervision; personnel at quarantine stations and areas; veterinarians; veterinarians or certified applicators at livestock and game facilities, zoos, wildlife facilities, animal rehabilitation centers; and wildlife professionals.

Read the entire label. This product must be used strictly in accordance with this label’s precautionary statements and use directions, as well as with all applicable state and federal laws and regulations. Please visit the Tanidil fact sheet for more information.

Use Period: This exemption is effective on April 27, 2026 and expires on April 27, 2029. No applications of Tanidil may be made under the emergency exemption before its effective date or after its expiration date.

Credelio, Credelio Quattro, Negasunt, Tanidil, Catron, Elanco and the diagonal bar logo are trademarks of Elanco or its affiliates. © 2026 Elanco or its affiliates